Laboratory for Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Herestraat 49, Leuven, Belgium.
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):593-604. doi: 10.1016/j.beem.2011.05.001.
Various epidemiological studies have shown an aetiological link between vitamin D deficiency and cancer incidence. The active metabolite of vitamin D, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], has potent anti-cancer activities both in vitro and in vivo. These anti-cancer effects are attained by regulating the transcription of numerous genes that are involved in different pathways to reduce tumorigenesis and are dependent on the cancer cell type. Besides reducing cell growth and inducing apoptosis, 1,25(OH)₂D₃ also inhibits angiogenesis and metastasis. Moreover, its potency to inhibit inflammation also contributes to its anti-tumoral activity. Here, we report the different ways in which 1,25(OH)₂D₃ interferes with the malignant processes that are activated in cancer cells.
多项流行病学研究表明，维生素 D 缺乏与癌症发病率之间存在病因联系。维生素 D 的活性代谢物 1,25-二羟基维生素 D₃[1,25(OH)₂D₃]，在体外和体内均具有强大的抗癌活性。这些抗癌作用是通过调节参与不同途径的众多基因的转录来实现的，从而减少肿瘤发生，并依赖于癌细胞类型。除了减少细胞生长和诱导细胞凋亡外，1,25(OH)₂D₃还抑制血管生成和转移。此外，其抑制炎症的能力也有助于其抗肿瘤活性。在这里，我们报告了 1,25(OH)₂D₃干扰癌细胞中激活的恶性过程的不同方式。
